Reference : Pharma-clinics. Comment je traite... II. Approche thérapeutique du cancer colorectal ...
Scientific journals : Article
Human health sciences : Oncology
http://hdl.handle.net/2268/2314
Pharma-clinics. Comment je traite... II. Approche thérapeutique du cancer colorectal métastatique
French
[en] Drug Clinics. How I Treat. II. Therapeutic Approaches to Metastatic Colorectal Cancer
Jerusalem, Guy mailto [Centre Hospitalier Universitaire de Liège - CHU > > Oncologie médicale >]
Bours, Vincent mailto [Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Génétique générale et humaine]
Fillet, Georges mailto [Université de Liège - ULiège > Département des sciences cliniques > Hématologie - Oncologie médicale]
Jun-1998
Revue Médicale de Liège
53
6
318-21
Yes (verified by ORBi)
National
0370-629X
[en] Since its introduction in 1953, 5-fluorouracil based chemotherapy remained the standard treatment in advanced colorectal cancer. Continuous infusion or biochemical modulation by folinic acid enhanced the therapeutic efficacy of this agent. Quality of life is limited by the toxicity of these regimens as well as by the frequent visits to the hospital during each cycle. Raltitrexed, a thymidylate synthase inhibitor, offers similar antitumoral activity together with a tolerability in comparison to standard 5-fluorouracil based chemotherapy and its simple dosage schedule also contributes to better quality of life. New chemotherapeutic agents are currently in development for the treatment of patients refractory to 5-fluorouracil. Irinotecan and oxaliplatin demonstrate promising activity.
http://hdl.handle.net/2268/2314

There is no file associated with this reference.

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.